Download PDF
Am J Perinatol 2013; 30(08): 681-688
DOI: 10.1055/s-0032-1331025
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Repeated Measures of Placental Growth Factor, Placental Protein 13, and A Disintegrin and Metalloprotease 12 at First and Second Trimesters for Preeclampsia Screening

Isabelle Boucoiran
1   Department of Obstetrics and Gynecology, CHU Sainte-Justine Research Center, Université de Montréal, Montreal, Quebec, Canada
,
Eva Suarthana
2   Department of Preventive Medicine, Research Center of Sacré-Coeur Hospital, Université de Montréal, Montréal, Québec, Canada
,
Evelyne Rey
1   Department of Obstetrics and Gynecology, CHU Sainte-Justine Research Center, Université de Montréal, Montreal, Quebec, Canada
,
Edgard Delvin
3   Department of Clinical Biochemistry, CHU Sainte-Justine Research Center, Université de Montréal, Montreal, Quebec, Canada
,
William B. Fraser
1   Department of Obstetrics and Gynecology, CHU Sainte-Justine Research Center, Université de Montréal, Montreal, Quebec, Canada
,
François Audibert
1   Department of Obstetrics and Gynecology, CHU Sainte-Justine Research Center, Université de Montréal, Montreal, Quebec, Canada
› Author Affiliations
Further Information

Publication History

06 June 2012

09 September 2012

Publication Date:
05 February 2013 (online)

Also available at
    Permissions and Reprints

Abstract

Objective To determine the utility of cross-trimester repeated measures of placental protein 13 (PP13), A disintegrin and metalloprotease 12 (ADAM12), and placental growth factor (PlGF) for preeclampsia (PE) screening.

Study Design A prospective cohort study of 893 nulliparous women who had serum sampling at 11 to 14 and 18 to 22 weeks. Biomarker levels were adjusted on maternal characteristics and gestational age. The accuracy and validity of maternal characteristics with single and repeated markers to predict PE were evaluated.

Results First-trimester PlGF was the best biomarker for PE (mean: 0.85 multiples of the expected median [MoM]) and early onset PE (0.79 MoM). First-trimester screening performances were not significantly improved by second-trimester markers. Area under the receiver operating characteristic curve was 0.73 (95% confidence interval [CI] 0.65 to 0.81) with first-trimester PlGF and 0.71 (95% CI 0.63 to 0.80) with first- and second-trimester PlGF (p = 0.301).

Conclusion Repeated measures of PlGF, ADAM12, and PP13 at second trimester did not improve PE screening compared with first-trimester measures.

Keywords

preeclampsia - screening - PlGF - PP13 - ADAM12

Notes

This work was supported by a grant from the Canadian Institutes of Health Research (CIHR, IHD82661). I.B. was supported as a clinical fellow by a grant of Sainte-Justine Hospital.


Presented at the 32nd Annual Meeting of the Society for Maternal-Fetal Medicine, Dallas, Texas, February 6 to 11, 2012.


 

  • References

  • 1 Wright DE, Bradbury I. Repeated measures screening for Down's syndrome. BJOG 2005; 112: 80-83
    CrossrefPubMedGoogle Scholar
  • 2 Wald NJ, Bestwick JP, Morris JK. Cross-trimester marker ratios in prenatal screening for Down syndrome. Prenat Diagn 2006; 26: 514-523
    CrossrefPubMedGoogle Scholar
  • 3 Wright D, Bradbury I, Malone F , et al. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment. Health Technol Assess 2010; 14: 1-80
    PubMedGoogle Scholar
  • 4 Bujold E, Roberge S, Lacasse Y , et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116 (2 Pt 1) 402-414
    CrossrefPubMedGoogle Scholar
  • 5 Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens 2010; 24: 104-110
    CrossrefPubMedGoogle Scholar
  • 6 Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330: 565
    CrossrefPubMedGoogle Scholar
  • 7 Audibert F, Boucoiran I, An N , et al. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol 2010; 203: 383 , e1–e8
    PubMedGoogle Scholar
  • 8 Luo ZC, An N, Xu HR, Larante A, Audibert F, Fraser WD. The effects and mechanisms of primiparity on the risk of pre-eclampsia: a systematic review. Paediatr Perinat Epidemiol 2007; 21 (Suppl. 01) 36-45
    CrossrefPubMedGoogle Scholar
  • 9 Audibert F, Benchimol Y, Benattar C, Champagne C, Frydman R. Prediction of preeclampsia or intrauterine growth restriction by second trimester serum screening and uterine Doppler velocimetry. Fetal Diagn Ther 2005; 20: 48-53
    CrossrefPubMedGoogle Scholar
  • 10 Stamilio DM, Sehdev HM, Morgan MA, Propert K, Macones GA. Can antenatal clinical and biochemical markers predict the development of severe preeclampsia?. Am J Obstet Gynecol 2000; 182: 589-594
    CrossrefPubMedGoogle Scholar
  • 11 Zwahlen M, Gerber S, Bersinger NA. First trimester markers for pre-eclampsia: placental vs. non-placental protein serum levels. Gynecol Obstet Invest 2007; 63: 15-21
    CrossrefPubMedGoogle Scholar
  • 12 Myatt L, Clifton RG, Roberts JM , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol 2012; 119: 1234-1242
    CrossrefPubMedGoogle Scholar
  • 13 Lambert-Messerlian GM, Palomaki GE, Neveux LM , et al. Early onset preeclampsia and second trimester serum markers. Prenat Diagn 2009; 29: 1109-1117
    CrossrefPubMedGoogle Scholar
  • 14 Giguère Y, Charland M, Bujold E , et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem 2010; 56: 361-375
    CrossrefPubMedGoogle Scholar
  • 15 Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn 2005; 25: 949-953
    CrossrefPubMedGoogle Scholar
  • 16 Dane B, Dane C, Kiray M, Cetin A, Koldas M, Erginbas M. Correlation between first-trimester maternal serum markers, second-trimester uterine artery Doppler indices and pregnancy outcome. Gynecol Obstet Invest 2010; 70: 126-131
    CrossrefPubMedGoogle Scholar
  • 17 Spencer K, Cowans NJ, Chefetz I, Tal J, Meiri H. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol 2007; 29: 128-134
    CrossrefPubMedGoogle Scholar
  • 18 Spencer K, Cowans NJ, Chefetz I, Tal J, Kuhnreich I, Meiri H. Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre-eclampsia. Prenat Diagn 2007; 27: 258-263
    CrossrefPubMedGoogle Scholar
  • 19 Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004; 104: 1367-1391
    CrossrefPubMedGoogle Scholar
  • 20 Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008; 32: 732-739
    CrossrefPubMedGoogle Scholar
  • 21 Akolekar R, Syngelaki A, Beta J, Kocylowski R, Nicolaides KH. Maternal serum placental protein 13 at 11–13 weeks of gestation in preeclampsia. Prenat Diagn 2009; 29: 1103-1108
    CrossrefPubMedGoogle Scholar
  • 22 Romero R, Kusanovic JP, Than NG , et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol 2008; 199: 122 , e1–e122, e11
    PubMedGoogle Scholar
  • 23 Chafetz I, Kuhnreich I, Sammar M , et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007; 197: 35 , e1–e7
    PubMedGoogle Scholar
  • 24 Gonen R, Shahar R, Grimpel YI , et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG 2008; 115: 1465-1472
    CrossrefPubMedGoogle Scholar
  • 25 Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007; 196: 239 , e1–e6
    PubMedGoogle Scholar
  • 26 Erez O, Romero R, Espinoza J , et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21: 279-287
    CrossrefPubMedGoogle Scholar
  • 27 Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007; 197: 244 , e1–e8
    PubMedGoogle Scholar
  • 28 Sibai BM, Koch MA, Freire S , et al. Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia?. Am J Obstet Gynecol 2008; 199: 268 , e1–e9
    PubMedGoogle Scholar
  • 29 Spencer K, Cowans NJ, Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn 2008; 28: 212-216
    CrossrefPubMedGoogle Scholar
  • 30 Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH. First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome. Obstet Gynecol 2008; 112: 1082-1090
    CrossrefPubMedGoogle Scholar
  • 31 Kuc S, Wortelboer EJ, van Rijn BB, Franx A, Visser GH, Schielen PC. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. Obstet Gynecol Surv 2011; 66: 225-239
    CrossrefPubMedGoogle Scholar
  • 32 Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX-XIV
    CrossrefPubMedGoogle Scholar
  • 33 Committee on Obstetric Practice; American College of Obstetricians and Gynecologists. ACOG committee opinion. Antenatal corticosteroid therapy for fetal maturation. Int J Gynaecol Obstet 2002; 78: 95-97
    CrossrefPubMedGoogle Scholar
  • 34 Hansen BE, Buster EH, Steyerberg EW, Lesaffre E, Janssen HL. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J Med Virol 2010; 82: 1135-1142
    CrossrefPubMedGoogle Scholar
  • 35 Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: Wiley; 2000
    CrossrefGoogle Scholar
  • 36 Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387
    CrossrefPubMedGoogle Scholar
  • 37 Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843
    CrossrefPubMedGoogle Scholar
  • 38 Levine RJ, Maynard SE, Qian C , et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683
    CrossrefPubMedGoogle Scholar
  • 39 Bestwick JP, George LM, Wu T, Morris JK, Wald NJ. The value of early second trimester PAPP-A and ADAM12 in screening for pre-eclampsia. J Med Screen 2012; 19: 51-54
    CrossrefPubMedGoogle Scholar